| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/18/2004 | WO2003102116A3 Oil-soluble pigment compositions |
| 03/18/2004 | WO2003097025B1 A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom |
| 03/18/2004 | WO2003097008A3 Transdermal delivery device for the administration of fentanyl |
| 03/18/2004 | WO2003092623A3 Calicheamicin derivative-carrier conjugates |
| 03/18/2004 | WO2003086442A3 Ophthalmic, pharmaceutical and other healthcare preparations with naturally occuring plant compounds, extracts and derivatives |
| 03/18/2004 | WO2003086305A3 Biodegradable peg-based polymer formulations in ocular applications |
| 03/18/2004 | WO2003084936A3 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| 03/18/2004 | WO2003082251A3 THE EFFERVESCENT PHARMACEUTICAL DOSAGE FORM OF ESTERS AND ESTER SALTS OF 6 α METHYLPREDNISOLONE SUCCINATE, PROCEDURE FOR ITS OBTAINING AND APPLICATION |
| 03/18/2004 | WO2003077885A3 Free-base formulations of local anesthetics |
| 03/18/2004 | WO2003059404A3 Preparation for wound healing and prevention of bandage adhesion to the wound |
| 03/18/2004 | WO2003053470A3 Pulsed bio-agent delivery systems based on degradable polymer solutions or hydrogels |
| 03/18/2004 | WO2003047546A3 Agent for treating excess weight in association with other indications |
| 03/18/2004 | WO2003047499A3 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 03/18/2004 | WO2003039435A3 Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections |
| 03/18/2004 | WO2003039434A3 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 03/18/2004 | WO2003025155A8 Fermentation product of cyptoporus volvatus and its preparation method and use |
| 03/18/2004 | WO2003023773A9 Drug delivery technology |
| 03/18/2004 | WO2003017818A3 Management of gastro-intestinal disorders |
| 03/18/2004 | WO2003015839A3 Devices for intrabody delivery of molecules and systems and methods utilizing same |
| 03/18/2004 | WO2003007869A3 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
| 03/18/2004 | WO2002085419A3 Bifunctional-modified hydrogels |
| 03/18/2004 | US20040054352 Vascular access port with physiological sensor |
| 03/18/2004 | US20040054313 Mixture with flow control agents; antiulcer agents |
| 03/18/2004 | US20040054184 Preservative for organs, synthetic blood |
| 03/18/2004 | US20040054015 Gel for treatment of skin diseases |
| 03/18/2004 | US20040054012 Which can be utilized in injectable preparations being stable over a long period, and containing, for example, phenolic or polyphenolic substances, amino alcohols or sulphur-containing substances |
| 03/18/2004 | US20040054001 For preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB, particularly psoriasis |
| 03/18/2004 | US20040053993 Compositions of tocol-soluble therapeutics |
| 03/18/2004 | US20040053978 Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| 03/18/2004 | US20040053975 Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night |
| 03/18/2004 | US20040053972 Medicinal compositions having improved absorbability |
| 03/18/2004 | US20040053936 Medicinal composition for oral use |
| 03/18/2004 | US20040053901 A skin permeation enhancer for enhancing absorption of a steroid hormone through the skin, containing an organic solvent, a fatty (C8-C20) alcohol ester of a hydroxy acid, a lower alkyl ester of hydroxy acid and a (C6-C18) fatty acid |
| 03/18/2004 | US20040053899 Method of preparing a pharmaceutical composition |
| 03/18/2004 | US20040053894 Improved water solubility; drug delivery; avoids irritation |
| 03/18/2004 | US20040053888 Cyclodextrin-containing pharmaceutical preparation |
| 03/18/2004 | US20040053887 Cellulose powder |
| 03/18/2004 | US20040053885 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 03/18/2004 | US20040053884 Comprises N-acylated hydroxyproline derivatives and glycosaminoglycans (chondroitin sulfate); for treatment of arthritis |
| 03/18/2004 | US20040053881 Adenosine derivatives and use thereof |
| 03/18/2004 | US20040053875 Comprises double-stranded RNA; extracted from HeLa cells |
| 03/18/2004 | US20040053873 Electroporation methods for introducing bioactive agents into cells |
| 03/18/2004 | US20040053863 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy |
| 03/18/2004 | US20040053853 Topiramate salts and compositions comprising and methods of making and using the same |
| 03/18/2004 | US20040053844 Peptide and osteogenetic accelerator |
| 03/18/2004 | US20040053818 Solution for removing cataracts via liquefracture |
| 03/18/2004 | US20040053817 Proinsulin C-peptide is present in an absorbable matrix of polyglycolide-lactide copolymers; antidiabetic agents |
| 03/18/2004 | US20040053408 Comprises anticoagulant/thrombolytic agent for selective dissolution of fibrin clots |
| 03/18/2004 | US20040053376 Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical and alimentary fields |
| 03/18/2004 | US20040052938 Electrostatic application of powder material to solid dosage forms in an electric field |
| 03/18/2004 | US20040052880 Comprises camomile extracts from plants of the genus Matricaria or Anthemis; solvent extraction; treating dermatitis/hay fever |
| 03/18/2004 | US20040052877 Comprises ginger perfume as a refrigerant; steam distillation; contact lens |
| 03/18/2004 | US20040052872 Comprises powder containing ash resulting from Symphytum officinale roots calcination in distilled water, with lidocaine for intramuscular administration; for treatment of autoimmune diseases |
| 03/18/2004 | US20040052865 Comprises encapsulation with calcium carbonate shell and intermediate layer of amphiphilic molecules (stearic/arachidic acid) surrounding the core; oil-in-water emulsions |
| 03/18/2004 | US20040052863 Comprises vitamin C, vitamin E, vitamin A (beta-carotene), zinc oxide, and cupric oxide; for promotion of retinal health |
| 03/18/2004 | US20040052859 Adding a water soluble drug into a solution, combining a curing agent and adding into an oil bath |
| 03/18/2004 | US20040052858 Microparticle coated medical device |
| 03/18/2004 | US20040052857 Vesicle encapsulating an aqueous system of a polymer and can exist as more than one phase depending on temperature and composition |
| 03/18/2004 | US20040052855 Pouring a dissolved biodegradable polymer and a drug in a low water soluble solvents, a surfactant and homogenizing, filtering, washing and freeze drying |
| 03/18/2004 | US20040052854 Porous substances and methods for producing the same |
| 03/18/2004 | US20040052853 High speed dissolve by reducing the molecular weight of the starting pectin |
| 03/18/2004 | US20040052852 Creatine dispersed in a matrix of sugars, sugar syrups, or sugar alcohols, a low set temperature carbohydrates, a hydrocolloid, a polyhydric alcohol solvent, a source of a (di)valent cation, water source; oral delivery |
| 03/18/2004 | US20040052851 Glassy matrix of a hydrophobic sugar alcohol, water soluble gelling gum and an active agent; transmucosal nicotine to reduce cravings |
| 03/18/2004 | US20040052849 Intercalate of a layered double hydroxide and a drug with an anionic group |
| 03/18/2004 | US20040052848 Single phase matrix of metformin and a controlled release excipient; maximum serum concentration is 3-12 hours after administration |
| 03/18/2004 | US20040052847 Oral dosage forms of water insoluble drugs and methods of making the same |
| 03/18/2004 | US20040052846 Delayed release pharmaceutical formulations |
| 03/18/2004 | US20040052845 Hydrogel-driven drug dosage form |
| 03/18/2004 | US20040052844 Core of 1-10% active ingredients, 0-80% diluents, 1-50% water soluble resins, 5-30% plasticizers, 0-50% adhesives and .5-5% lubricants and a film coating .5-80% forming agents, .5-30% plasticizers and .5-20% antisticking agents |
| 03/18/2004 | US20040052843 Controlled release dosage forms |
| 03/18/2004 | US20040052842 Delayed and immediate release dosage forms; once a day administration; maximum serum concentration is reached in </=12 hours |
| 03/18/2004 | US20040052841 Pharmaceutical preparation with retarding active ingredient release, method for its production and its use |
| 03/18/2004 | US20040052840 Preparations for oligonucleotide transfer |
| 03/18/2004 | US20040052839 Mixing non-gelatin hydrocolloid, water, and a plasticizer into a homogeneous composition of >/= 40% water, extracting water to 25% and forming the dried portion into a film; edible; enrobing and/or encapsulating oral dosage forms |
| 03/18/2004 | US20040052838 Erythropoietin liposomal dispersion |
| 03/18/2004 | US20040052837 Lipid conjugated anti-cancer drugs and methods of use thereof |
| 03/18/2004 | US20040052836 3-9% weight of a glyceride and .5-3% weight synthetic phospholipid containing 2-2.5% weight of a compound; average particle size of 3-450 microns and gel time of >/= 24 hours at room temperature; drug delivery vehicle |
| 03/18/2004 | US20040052835 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 03/18/2004 | US20040052832 Acid-labile active ingredient is present in the individual active ingredient units in a matrix composed of a mixture of solid praffin, and one or more substances form fatty alcohol, fatty ester and triglyceride |
| 03/18/2004 | US20040052825 Vehicle for amorphus drug dose delivery, containing a hydrophobic material and a polyol; dissolving the polyol and hydrophobic bioactive material in an organic/aqueous solvent, removing the solvent and forming the vehicle |
| 03/18/2004 | US20040052824 Micelles containing at least a very lipophilic principle, enabling to enhance bioavailability of active principles insoluble in aqueous solvents called Micellar improved drug delivery solutions |
| 03/18/2004 | US20040052823 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 03/18/2004 | US20040052819 Addition of histidine amino acids to the cytoplasmic domains of membrane and viral envelope proteins for the purpose of solubilizing, and/or reconstituting viral envelope proteins in lipid containing vesicles |
| 03/18/2004 | US20040052767 Method for cell adhesion and wound healing |
| 03/18/2004 | US20040052750 Topical applying; adjust collagen biosynthesis; mixture of phenytoin, valproic acid, cyclosporin, nifedipine, diltazem,verapamil hydrochloride and amoldipine |
| 03/18/2004 | US20040052734 Process for providing a stable crystalline form of salbutamol |
| 03/18/2004 | US20040052733 Pharmaceutical compositions for inhalation |
| 03/18/2004 | US20040052732 Synergistic mixture of antiserotonine agents and glucocorticoids; inhalation |
| 03/18/2004 | US20040052731 Adjustment lipophilic of drug; prevent drug abuse; enteric coating |
| 03/18/2004 | US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 03/18/2004 | US20040051192 Manufacturing method for oral quick-dissolving seamless capsule |
| 03/18/2004 | US20040050964 Dispensing device |
| 03/18/2004 | US20040050960 Metered dose inhaler for salemeterol xinafoate |
| 03/18/2004 | US20040050402 Device for applying active principles for pharmaceutical or cosmetic purposes |
| 03/18/2004 | DE10242367A1 Thermolabile liposomes with good stability in serum, e.g. for release of drugs or contrast agents in hyperthermic areas around tumors, formed from phosphatidyl choline(s) and phosphatidyl oligoglycerol |
| 03/18/2004 | CA2707068A1 Clear ophthalmic solution comprising latanoprost as active ingredient |
| 03/18/2004 | CA2707067A1 Clear ophthalmic solution comprising latanoprost as active ingredient |
| 03/18/2004 | CA2497975A1 Combined immediate release and extended release analgesic composition |
| 03/18/2004 | CA2497896A1 Pravastatin pharmaceutical formulations and methods of their use |
| 03/18/2004 | CA2497832A1 Pharmaceuticals formulations and methods for modified release of statin drugs |